<DOC>
	<DOCNO>NCT00423267</DOCNO>
	<brief_summary>To evaluate safety posaconazole ( POS ) treatment coccidioidomycosis . Period A consisted 2 blind arm , posaconazole fluconazole . Recruitment stop , participant Period A may eligible roll open-label , non-comparitive Period B . During Period B , participant receive posaconazole treatment duration exceed 12 month .</brief_summary>
	<brief_title>POS v FLU First Line Treatment Coccidioidomycosis ( Study P04558Am1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Coccidioidomycosis</mesh_term>
	<mesh_term>Coccidiosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Thirteen year age old , 34 kg ( 75 lb ) , either sex , race ; Coccidioides immitis ( C. immitis ) Coccidioides posadasii ( C. posadasii ) identify culture microscopic examination skeletal disease , chronic active pulmonary disease , soft tissue disease ; Coccidioidomycosis score &gt; =6 ; Clinical laboratory safety test within normal limit clinically acceptable sponsor ; Free clinically significant disease would interfere study evaluation ; Willing give write informed consent able adhere study medication dose , mandatory procedure ( include human immunodeficiency virus ( HIV ) test ) , visit schedule ; Able swallow food nutritional supplement ; Use medically accept method contraception ; Negative serum pregnancy test Screening negative urine pregnancy test Randomization ; Women childbearing potential currently sexually active must agree use medically accept method contraception become sexually active participate study . Key Exclusion Criteria Excluded Medications Enrollment Medications know interact POS FLU may lead serious life threaten side effect within 7 day prior initiate study drug ; Medications know low serum concentration/efficacy azole antifungal within 7 day prior study drug start ; Prior investigational drug use biologic product administration within 30 day study drug start ; Prior antifungal treatment current episode infection total cumulative dose &gt; =8 g azole , &gt; =4 mg/kg amphotericin B deoxycholate , &gt; =20 mg/kg lipid amphotericin B ; Antiretrovirals substrates CYP3A4 administer HIVpositive subject , currently know POS FLU may affect drug potential cause adverse reaction . Excluded Concomitant Conditions Immediately lifethreatening coccidioidomycosis ; Confirmed suspect meningeal coccidioidomycosis ; Pulmonary coccidioidomycosis HIVnegative subject less 3 month ; Any condition requiring use prohibit drug ; Cluster Differentiation 4 ( CD4 ) count &lt; 200 cells/mm3 autoimmune deficiency syndrome ( AIDS ) define illness HIVpositive subject prior 30 day . Excluded Baseline Laboratory Studies Moderate severe liver dysfunction ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) ) total bilirubin level direct bilirubin &gt; 3 time ULN plus ALT AST &gt; 2 time ULN ( Hy 's Rule ) ; Moderate severe renal dysfunction ( creatinine clearance ( CrCl ) &lt; 20 mL/min ) dialysis require expect require within study period ; Electrocardiogram ( ECG ) prolong QTc interval manual reading : QTc &gt; 450 msec male QTc &gt; 470 msec female . General Exclusion Criteria Prior enrollment study POS study ; Failed treatment FLU POS time past ; History hypersensitivity idiosyncratic reaction azole drug therapy ; Women pregnant , intend become pregnant , breastfeed ; Situation condition may interfere optimal participation study ; Part staff personnel directly involve study ; Family member investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>